News

EuroSpA publication D8.1

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable? Click here to access full article

EuroSpA publication D3.1

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response Click here to access full article

EuroSpA publication 1.3

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment Click here to access full article

EuroSpA publication 2.1

Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis Click here to access full article This publication is featured in Editor's Picks Spotlight by the Journal of Rheumatology, see the interview with Lykke Ørnbjerg here:

EuroSpA publication D1.1

Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network Click here to access full article

EuroSpA publication A1.1

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice Click here to access full article

EuroSpA publication D1.2

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network Click here to access full article

EuroSpA publication E.1

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration Click here to access full article

EuroSpA publication 1.4

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 1.4, interview with Louise Linde Plain language summary text: [...]

EuroSpA publication A2.1

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Click here to access full article Plain language summary (in danish) Featured in Magasinet om Rygsøjlegigt, May 2024

EuroSpA publication 4.1

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 4.1, interview with Louise Linde Plain language summary [...]

EuroSpA publication 2.2

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 2.2, interview with Lykke Ørnbjerg Plain language summary text: [...]

EuroSpA publication 4.2

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration Click here to access full article Plain language summary: “Age, sex, smoking status and other common factors may predict which patients with axial spondyloarthritis achieve inactive disease when treated with TNF [...]

EuroSpA publication 1A

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response Click here to access full article

EuroSpA publication 3.2

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis Click here to access full article

EuroSpA publication 6.1

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries Click here to access full article

EuroSpA publication 6.2

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration Click here to access full article

EuroSpA publication 2.3

Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis Click here to access full article

EuroSpA publication 3.1

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration Click here to access full article

EuroSpA publication 1.1

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA Click here to access full article

Go to Top